Evaluation of 225Ac-DOTATATE for treatment of lung carcinoid tumors
Researcher: David Morse, PhD Location: Moffitt Cancer Center State: Florida Year: 2018 Status: Active Grant Duration: 1 year Award: Pilot Award
Leave it blank
Researchers will test a novel radiotherapy, 225Ac-dotatate, a derivative of 177Lu-dotatate in PRRT for lung NETs in laboratory models. This therapy emits alpha (α) particles instead of beta (β). Alpha particles are bigger, higher powered, with a shorter reach, which researchers hope will be more effective in killing lung NET cells with decreased toxicity in surrounding normal tissues. Laboratory tests will help evaluate the therapy’s safety and efficacy to prepare for potential testing in humans.
NET Research Foundation
321 Columbus Avenue, Suite 5R
Boston MA 02116